Your browser doesn't support javascript.
loading
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study.
Lemoine, Maud; Assoumou, Lambert; Girard, Pierre-Marie; Valantin, Marc Antoine; Katlama, Christine; De Wit, Stephane; Campa, Pauline; Rougier, Hayette; Meynard, Jean-Luc; Necsoi, Coca; Huefner, Anja D; Van Luzen, Jan; Schulze Zur Wiesch, Julian; Bastard, Jean-Philippe; Fellahi, Soraya; Mauss, Stefan; Stankov, Metodi V; Baumgarten, Axel; Post, Gerrit; Serfaty, Lawrence; Ratziu, Vlad; Menu, Yves; Schlue, Jerome; Bedossa, Pierre; Capeau, Jacqueline; Costagliola, Dominique; Behrens, Georg; Ingiliz, Patrick.
Afiliação
  • Lemoine M; Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Section of Hepatology, St Mary's Hospital, NHS Trust, Imperial College London, United Kingdom. Electronic address: m.lemoine@imperial.ac.uk.
  • Assoumou L; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
  • Girard PM; APHP Saint-Antoine Hospital, Department of Infectious Disease and Tropical Medicine, Sorbonne University, Paris, France.
  • Valantin MA; APHP(,) Pitie-Salpetriere Hospital, Department of Infectious Disease and Tropical Medicine, Sorbonne University, Paris, France.
  • Katlama C; APHP(,) Pitie-Salpetriere Hospital, Department of Infectious Disease and Tropical Medicine, Sorbonne University, Paris, France.
  • De Wit S; Service des Maladies Infectieuses, CHU Saint-Pierre, Université Libre de Bruxelles, Belgium.
  • Campa P; APHP Saint-Antoine Hospital, Department of Infectious Disease and Tropical Medicine, Sorbonne University, Paris, France.
  • Rougier H; APHP Saint-Antoine Hospital, Department of Infectious Disease and Tropical Medicine, Sorbonne University, Paris, France.
  • Meynard JL; APHP Saint-Antoine Hospital, Department of Infectious Disease and Tropical Medicine, Sorbonne University, Paris, France.
  • Necsoi C; Service des Maladies Infectieuses, CHU Saint-Pierre, Université Libre de Bruxelles, Belgium.
  • Huefner AD; University Medical Center, Department of Hepatology and Gastroenterology, Hambourg, Germany.
  • Van Luzen J; University Medical Center, Department of Hepatology and Gastroenterology, Hambourg, Germany.
  • Schulze Zur Wiesch J; University Medical Center, Department of Hepatology and Gastroenterology, Hambourg, Germany.
  • Bastard JP; Sorbonne Université, INSERM UMR_S938, CRSA, ICAN, Paris, France; APHP, Tenon Hospital, Department of Biochemistry and Hormonology, Paris, France; Université Paris-Est Créteil Val-de-Marne, Créteil, France; APHP, Hôpitaux Universitaires Henri Mondor, Département de Biochimie-Pharmacologie-Biologie Mo
  • Fellahi S; Sorbonne Université, INSERM UMR_S938, CRSA, ICAN, Paris, France; APHP, Tenon Hospital, Department of Biochemistry and Hormonology, Paris, France; APHP, Hôpitaux Universitaires Henri Mondor, Département de Biochimie-Pharmacologie-Biologie Moléculaire-Génétique Médicale, Créteil, France.
  • Mauss S; Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
  • Stankov MV; Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Baumgarten A; Center for Infectiology, Berlin, Germany.
  • Post G; Hepatology Department, Charité University Medical Center, Berlin, Germany.
  • Serfaty L; Saint-Antoine Hospital, Department of Hepatology, University of Paris, France.
  • Ratziu V; Pitie-Salpetriere Hospital, Department of Hepatology, University of Paris, France.
  • Menu Y; Saint-Antoine Hospital, Department of Radiology, University of Paris, France.
  • Schlue J; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Bedossa P; Beaujon Hospital, Department of Histopathology, Clichy, France.
  • Capeau J; Sorbonne Université, INSERM UMR_S938, CRSA, ICAN, Paris, France; APHP, Tenon Hospital, Department of Biochemistry and Hormonology, Paris, France.
  • Costagliola D; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
  • Behrens G; Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Ingiliz P; Center for Infectiology, Berlin, Germany; Hepatology Department, Charité University Medical Center, Berlin, Germany.
Clin Gastroenterol Hepatol ; 21(3): 713-722.e3, 2023 03.
Article em En | MEDLINE | ID: mdl-35436624
ABSTRACT
BACKGROUND &

AIMS:

Nonalcoholic fatty liver disease (NAFLD) is a growing concern in the aging population with human immunodeficiency virus (HIV). Screening for NAFLD is recommended in patients with metabolic risk factors or unexplained transaminitis. This study aimed to prospectively assess the prevalence and associated factors of liver steatosis and advanced fibrosis (AF) in HIV-monoinfected patients at risk of NAFLD.

METHODS:

We conducted a multicenter study in HIV-monoinfected patients, nonexcessive drinkers with metabolic syndrome, and/or persistently elevated liver enzymes, and/or clinical lipodystrophy. All participants had magnetic resonance imaging proton density fat fraction (MRI-PDFF), Fibroscan/controlled attenuation parameter (CAP), and cytokine and genetic analysis.

RESULTS:

From March 2014 to November 2015, we enrolled 442 participants and analyzed 402 male (85%); median age, 55 years (interquartile range [IQR], 50-61 years); body mass index, 27.0 kg/m2 (IQR, 23.6-28.7 kg/m2); metabolic syndrome (67%); and CD4 cell count, 630/mm3 (IQR, 510-832/mm3). Overall 257 of 402 (64%) had NAFLD (MRI-PDFF ≥5%). Among them, 11.3% had a liver stiffness ≥9.6 kPa, suggestive of AF. Multivariable analysis identified 7 factors of steatosis high CD4-cell count (odds ratio [OR], 4.04; 95% confidence interval [CI], 1.92-8.51), high leptin level (OR, 2.12; 95% CI, 1.14-3.93), non-CC PNPLA3s738409 genetic polymorphism (OR, 1.92; 95% CI, 1.11-3.33), low high-density lipoprotein (OR, 1.83; 95% CI, 1.03-3.27), high triglycerides (OR, 1.48; 95% CI, 1.18-1.84), elevated alanine transaminase (OR, 1.23; 95% CI, 1.16-1.31), and hyper ferritinemia (OR, 1.05; 95% CI, 1.03-1.07). Two factors were associated with AF high body mass index (OR, 1.23 ; 95% CI, 1.07-1.42 ; P = .005, and elevated aspartate aminotransferase (OR, 1.03; 95% CI, 1.01-1.05; P = .001). Using MRI-PDFF as a reference, CAP (best cutoff, 280 dB/m) had good accuracy (area under the receiver operating characteristic curve = 0.86; 95% CI, 0.82-0.90) for the diagnosis of moderate to severe steatosis.

CONCLUSIONS:

In a large cohort of HIV-moninfected patients at risk of NAFLD, steatosis is present in two-thirds of cases, and around 10% have AF. The CAP technique is accurate for screening steatosis in this population.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Infecções por HIV / Síndrome Metabólica / Técnicas de Imagem por Elasticidade / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Infecções por HIV / Síndrome Metabólica / Técnicas de Imagem por Elasticidade / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article